

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb253</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Novel Combinations of Synthesized ZnO NPs and Ceftazidime: Evaluation of their Activity Against Standards and New Clinically Isolated Pseudomonas aeruginosa</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Isaei</surname><given-names>Elham</given-names></name></contrib><aff>Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mansouri</surname><given-names>Shahla</given-names></name></contrib><aff>Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Fereshteh</given-names></name></contrib><aff>Kerman Pharmaceutics Research Center and Department of Pharmaceutics, Kerman University of Medical Sciences, Kerman, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Taheritarigh</surname><given-names>Sadegh</given-names></name></contrib><aff>Genetics Division, Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Zohreh</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>8</volume>
      <issue>4</issue>
      <fpage>169</fpage>
      <lpage>174</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>2</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;Background: Antibiotic resistant bacteria can be considered as a main problem in infection management. Zinc oxide nanoparticles (ZnO NPs), individually or in combination with antibiotics, can be considered as good candidates for struggling against drug resistant bacteria.&lt;br /&gt;
Methods: In this study, Zinc oxide nanoparticles were synthesized using sol-gel method in low temperature as a cost effective procedure and characterized by X-ray diffraction and Scanning Electron Microscopy. Antibacterial activity of 9 new combinations of Zinc oxide nanoparticles and ceftazidime was assessed against standards and new clinically isolated multi drug resistant &lt;em&gt;Pseudomonas aeruginosa (P. aeruginosa)&lt;/em&gt;, in order to evaluate enhancement effect of synthesized Zinc oxide nanoparticles on antibacterial activity of ceftazidime.&lt;br /&gt;
Results: The results indicated that desirable effects can be seen at 6 and 7 &lt;em&gt;mM&lt;/em&gt; of Zinc oxide nanoparticles (60 to 100% inhibition). Moreover, after evaluation of 9 new combinations with various concentrations of both components, it was demonstrated that Zinc oxide nanoparticles can enhance the antibacterial activity of ceftazidime, against some bacterial strains of &lt;em&gt;P. aeruginosa&lt;/em&gt;. The highest activity was observed with the concentration of 20 &lt;em&gt;&amp;mu;g/ml&lt;/em&gt; ceftazidime in the presence of 5, 6 or 7 &lt;em&gt;mM&lt;/em&gt; of Zinc oxide nanoparticles.&lt;br /&gt;
Conclusion: Zinc oxide nanoparticles in appropriate concentrations can be proposed as new and promising candidates for overcoming bacterial resistance.&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
